- Home
- VOR vs TLSA Comparison
VOR vs TLSA Comparison
Compare VOR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VOR | TLSA |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 207.1M | 182.7M |
| IPO Year | 2021 | 2000 |
Fundamental Metrics
Financial Performance| Metric | VOR | TLSA |
|---|---|---|
| Price | $15.70 | $1.73 |
| Analyst Decision | Buy | |
| Analyst Count | 10 | 0 |
| Target Price | ★ $64.78 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 282.7K |
| Earning Date | 11-13-2025 | 05-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.62 | $0.63 |
| 52 Week High | $65.80 | $2.60 |
Technical Indicators
Market Signals| Indicator | VOR | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 59.07 | 57.68 |
| Support Level | $13.00 | $1.32 |
| Resistance Level | $14.64 | $1.58 |
| Average True Range (ATR) | 1.45 | 0.13 |
| MACD | 0.30 | 0.02 |
| Stochastic Oscillator | 97.28 | 82.56 |
Price Performance
Historical ComparisonAbout VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.